Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $46.37 and last traded at $44.98, with a volume of 412360 shares changing hands. The stock had previously closed at $44.18.
Gemini Therapeutics Trading Down 2.5 %
The firm has a market cap of $1.88 billion, a PE ratio of -43.41 and a beta of -0.12. The company has a 50 day moving average price of $33.64 and a 200 day moving average price of $50.11.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Further Reading
- Five stocks we like better than Gemini Therapeutics
- How to Use Stock Screeners to Find Stocks
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Do ETFs Pay Dividends? What You Need to Know
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- How to Effectively Use the MarketBeat Ratings Screener
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
